Co-Diagnostics Inc (CODX)

[Opti Mist]

And more from Dwight: "The global addressable TB diagnostics market is expected to grow from 2.07 billion in 2022 to 3.13 billion by 2029. We believe the interest among NGOs and our new platform partially reflects their refocus on eradicating TB. We regard these grants as being in lockstep with the natural evolution of our vision and strategic plan. The company’s first CE marking received 5 years ago this July was for our Logix Smart MTB test built using our CoPrimer’s technology. The difference between then and now is we have grown beyond mere aspirations and now find ourselves fully in execution mode. With internationally recognized technology, world renowned experts and a point-of-care platform different from anything the world has ever seen, I want to emphasize that our new platform has been designed and engineered to be versatile and durable, with long-term disruptive potential as a diagnostic medical device. Harnessing the power of our patented battle tested CoPrimer’s technology coupled with other proprietary IP, we believe this platform sets a new benchmark for compact point-of-care testing that unlocks the multiplexing potential of real-time PCR."

Opti